$SHC

Sotera Health Co

Sotera Health provides sterilization, laboratory testing and advisory services for the healthcare industry, serving medical device and pharmaceutical companies as well as customers in food safety and other markets. Its businesses are Sterigenics and Nordion, which make up its sterilization services segment, and Nelson Labs, which provides lab testing and advisory services. Sterigenics offers terminal sterilization using gamma irradiation, EO processing and electron beam irradiation, along with microbial reduction and other radiation processing services. Nordion supplies cobalt-60 sources, gamma irradiation systems and related technical, logistics and source-return services. Nelson Labs provides more than 900 microbiological and analytical chemistry tests, plus product development, validation and regulatory advisory services. Sotera Health earns fees for sterilization, testing and advisory work, and sells cobalt-60 sources and irradiation systems. Its services support products and processes across customer product lifecycles, from development and validation to routine quality control. The company operates 62 facilities worldwide and is headquartered in Broadview Heights, Ohio.

AlphAI earnings readThird quarter 2026 and nine months ended September 30, 2026 · NOV 3Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
1
0

No SEC Form 4 filings for $SHC in the last 30 days.

See all $SHC insider activity →
Low

Jefferies reiterates Sotera Health stock buy rating at $20 target

Jefferies maintained a Buy rating on Sotera Health (NASDAQ:SHC) with a $20 target, citing CEO Alton Shader's presentation. The company reported Q3 2026 earnings of $0.29 per share, beating estimates, with revenue at $324.89M. Sotera Health has a 54.6% gross margin and a 3.13 current ratio, and plans growth through cash flow deployment. The stock is undervalued with a PEG ratio of 0.13, according to InvestingPro.

Sotera Health Earnings Call Signals Growth Despite Mixed Trends

Sotera Health (SHC) reported Q3 revenue of $325M (+4.4% YoY) and adjusted EBITDA of $171M (+3.9%). Sterigenics and Nelson Labs drove growth, while Nordion faced declines. Management reaffirmed 2026 guidance but noted European medical device weakness and FX pressures.

SHC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SHC (Sotera Health Co). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent SHC coverage spans earnings, financial news and market movers.

What's driving SHC

  • Analyst reiteration with a defined $20 target supports the bull case, but the article is primarily a valuation narrative rather than a new company catalyst.

    investing.com · Nov 18, 2026

  • Reaffirmed outlook may support modest price stability, but mixed segment trends could limit upside.

    tipranks.com · Nov 15, 2026

  • JP Morgan kept Sotera Health at Underweight, reducing its price target to $15 from $17, citing an 11.8% decrease. This implies a 6.4% downside from the Nov 3 close of $16.03.

    tradingview.com · Nov 4, 2026

  • The PT cut is likely to weigh on near-term sentiment, even with the unchanged Overweight stance.

    tradingview.com · Nov 4, 2026

  • The beat‑but‑no‑raise earnings and reaffirmed guidance triggered immediate selling pressure.

    investing.com · Nov 3, 2026

AlphAI scores every news story that mentions SHC with an AI model for sentiment and relevance, and aggregates insider trades from Sotera Health Co's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SHC

Score

Jefferies reiterates Sotera Health stock buy rating at $20 target

Jefferies maintained a Buy rating on Sotera Health (NASDAQ:SHC) with a $20 target, citing CEO Alton Shader's presentation. The company reported Q3 2026 earnings of $0.29 per share, beating estimates, with revenue at $324.89M. Sotera Health has a 54.6% gross margin and a 3.13 current ratio, and plans growth through cash flow deployment. The stock is undervalued with a PEG ratio of 0.13, according to InvestingPro.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMedEarnings

Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results

Sotera Health Co (SHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results • Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis (1) , compared to Q3 2025 • Q3 2026 net income of $58 million or $0.20 per diluted share • Q3 2026 Adjuste

Here’s Why Sotera Health Company (SHC) Surges 25% in Q2

Broyhill Asset Management's Q2 2026 investor letter highlights Sotera Health Company (SHC) as a top performer, with shares surging 25%. The company, which provides healthcare sterilization and testing services, reported revenue and earnings beats, and reaffirmed guidance. SHC closed at $18.52 per share on September 14, 2026, with a market cap of $5.29 billion.

Related tickers